首页> 外国专利> METHOD FOR DETERMINING THE RISK OF HYPERCOAGULABILITY IN PATIENTS WITH PORTAL HYPERTENSION OF CYRRHOTIC GENESIS AFTER PORTOSYSTEMIC SHUNT PLACEMENT

METHOD FOR DETERMINING THE RISK OF HYPERCOAGULABILITY IN PATIENTS WITH PORTAL HYPERTENSION OF CYRRHOTIC GENESIS AFTER PORTOSYSTEMIC SHUNT PLACEMENT

机译:骨膜增生症患者放置门脉高压性门脉高压症的患者的高可凝性风险测定方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to surgery, and can be used to determine the risk of hypercoagulation in patients with hepatic cirrhosis complicated by portal hypertension after portosystemic shunt placement. Find out from the patient the time that has passed since the ascertainment of esophageal-gastric bleeding. Evaluate the severity class of hepatic cirrhosis by Child-Pugh. Determine the parameters by the method of thrombodynamics: the rate of formation of the blood clot, the growth inhibition of the blood clot, the initial growth rate of the blood clot, the steady growth rate of the blood clot, the size of the clot after 30 min, the density of the clot, the time of appearance of spontaneous clots. Following values are determined: the level of D-dimer, the level of SFMCs (soluble fibrin monomer complexes). Triplex scan of the vessels of the portal zone is performed and the following parameters are determined: the linear velocity of blood flow in the portal vein, hepatopetal or hepatofugal character of the blood flow in the portal vein, the diameter of the portal vein, and the rate of blood flow in the shunt after TIPS procedure (transjugular intrahepatic portosystemic shunting). Estimate the received indicators in points. Sum all the points. At the sum of scores is less than or equal to 5, the patient is referred to the risk group A – there is no risk of hypercoagulability. At a total of 6–10 points, the patient is referred to the risk group B – the risk of hypercoagulability is moderate. At the sum of 11–15 points, the patient is referred to the risk group C – the risk of hypercoagulability is high.;EFFECT: method allows to identify the risk of hypercoagulability, to improve the results of surgical treatment of patients with hepatic cirrhosis complicated by portal hypertension after portosystemic shunt placement by evaluating the complex of the most significant indicators.;1 cl, 11 tbl, 3 ex
机译:技术领域本发明涉及医学,即涉及外科手术,并且可用于确定在门体系统分流放置后并发门脉高压的肝硬化患者的高凝风险。从患者中找出确定食管胃出血的时间。通过Child-Pugh评估肝硬化的严重程度等级。通过血栓动力学方法确定参数:血凝块的形成速率,血凝块的生长抑制,血凝块的初始生长速率,血凝块的稳定生长速率,血凝块的大小30分钟,凝块的密度,自发凝块出现的时间。确定以下值:D-二聚体的水平,SFMCs(可溶性纤维蛋白单体复合物)的水平。对门静脉区的血管进行三重扫描,并确定以下参数:门静脉血流的线速度,门静脉血流的肝瓣或肝叶特征,门静脉直径和TIPS手术(经颈静脉肝内门体分流)后分流中的血流速率。以点为单位估计收到的指标。对所有要点求和。得分总和小于或等于5时,患者被转入A组风险–没有高凝风险。在总共6-10分的情况下,将患者转入B组风险–高凝风险为中等。总分为11–15分,将患者转入C风险组–高凝风险。;效果:该方法可识别高凝风险,以改善肝硬化患者的手术治疗结果通过评估最重要指标的复杂性,在门体系统分流放置后并发门脉高压。[1 cl,11 tbl,3 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号